ImageneBio, Inc. Debt Securities, Available-for-sale, Amortized Cost
ImageneBio, Inc. (IMA) had Debt Securities, Available-for-sale, Amortized Cost of $41.53 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $41.53M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $41.18M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $40.73M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $39.33M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $41.53M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $41.18M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $40.73M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $39.33M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $37.29M 10-Q · filed 2025-07-24 |
| 2025-03-31 | $77.19M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $84.92M 10-Q · filed 2025-07-24 |
| 2024-09-30 | $92.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $101.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $104.81M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $55.62M 10-K · filed 2025-03-06 |
| 2023-09-30 | $94.89M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $93.52M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $123.41M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $97.79M 10-K · filed 2024-03-12 |
| 2022-09-30 | $110.96M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $145.43M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $171.97M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |